Renske D.M. Steenbergen

Prof. Renske D.M. Steenbergen

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2014 in Nature Reviews Cancer
Verified
Journal Article
Closed access
Renske D.M. SteenbergenRenske D.M. Steenbergen
Renske D.M. Steenbergen
PSPeter J. F. Snijders
Peter J. F. Snijders
DHDaniëlle A. M. Heideman
Daniëlle A. M. Heideman
CMChris J. L. M. Meijer
Chris J. L. M. Meijer

17 December 2005 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
PSPeter Jf Snijders
Peter Jf Snijders
Renske D.M. SteenbergenRenske D.M. Steenbergen
Renske D.M. Steenbergen
DHDaniëlle Am Heideman
Daniëlle Am Heideman
CMChris Jlm Meijer
Chris Jlm Meijer
Persistent infection with a high‐risk human papillomavirus (hrHPV) is generally accepted as a necessary cause of cervical cancer. However, cervical cancer is a rare complication of an hrHPV infection since most such infections are transient, not even giving rise to cervical lesions. On average, it takes 12–15 years before a persistent hrHPV infection may ultimately, via consecutive premalignant stages (ie CIN lesions), lead to an overt cervical carcinoma. This argues that HPV‐induced cervical carcinogenesis is multi‐step in nature. In this review, the data from hrHPV‐mediated in vitro transformation studies and those obtained from analysis of clinical specimens have been merged into a cervical cancer progression model. According to this model, a crucial decision maker in the early stages following infection involves individual susceptibility for certain HPV types depending on the genetic make‐up of immune surveillance determinants. Once a CIN lesion has developed, altered transcriptional regulation of the viral E6/E7 oncogenes, resulting in genomic instability and distinguishing the process of cell transformation from a productive viral infection, probably provides the subsequent important step towards malignancy. The additional (epi)genetic alterations that subsequently accumulate in high‐grade CIN lesions may result in overt malignancy via immortality and growth conditions that gradually become less sensitive to growth‐modulating influences mediated by cytokines and cell–cell and cell–matrix adhesions. The potential implications of hrHPV testing and some other biomarkers deduced from this model for cervical screening and the clinical management of CIN disease are also discussed. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

10 February 2009 in Genome Research
Verified
Journal Article
Closed access
PDF file
Agustin FernandezAgustin Fernandez
Agustin Fernandez
CRCecilia Rosales
Cecilia Rosales
Pilar López-NievaPilar López-Nieva
Pilar López-Nieva
OGOsvaldo Graña
Osvaldo Graña
EBEsteban Ballestar
Esteban Ballestar
MEManel Esteller
Manel Esteller
The natural history of cancers associated with virus exposure is intriguing, since only a minority of human tissues infected with these viruses inevitably progress to cancer. However, the molecular reasons why the infection is controlled or instead progresses to subsequent stages of tumorigenesis are largely unknown. In this article, we provide the first complete DNA methylomes of double-stranded DNA viruses associated with human cancer that might provide important clues to help us understand the described process. Using bisulfite genomic sequencing of multiple clones, we have obtained the DNA methylation status of every CpG dinucleotide in the genome of the Human Papilloma Viruses 16 and 18 and Human Hepatitis B Virus, and in all the transcription start sites of the Epstein-Barr Virus. These viruses are associated with infectious diseases (such as hepatitis B and infectious mononucleosis) and the development of human tumors (cervical, hepatic, and nasopharyngeal cancers, and lymphoma), and are responsible for 1 million deaths worldwide every year. The DNA methylomes presented provide evidence of the dynamic nature of the epigenome in contrast to the genome. We observed that the DNA methylome of these viruses evolves from an unmethylated to a highly methylated genome in association with the progression of the disease, from asymptomatic healthy carriers, through chronically infected tissues and pre-malignant lesions, to the full-blown invasive tumor. The observed DNA methylation changes have a major functional impact on the biological behavior of the viruses.

26 June 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SWSaskia Wilting
Saskia Wilting
RBRobert Aa van Boerdonk
Robert Aa van Boerdonk
FHFlorianne E Henken
Florianne E Henken
CMChris Jlm Meijer
Chris Jlm Meijer
BDBegoňa Diosdado
Begoňa Diosdado
Renske D.M. SteenbergenRenske D.M. Steenbergen
Renske D.M. Steenbergen
Background: A substantial number of microRNAs (miRNAs) is subject to epigenetic silencing in cancer. Although epigenetic silencing of tumour suppressor genes is an important feature of cervical cancer, little is known about epigenetic silencing of miRNAs. Since DNA methylation-based silencing of hsa-miR-124 occurs in various human cancers, we studied the frequency and functional effects of hsa-miR-124 methylation in cervical carcinogenesis. Results: Quantitative MSP analysis of all 3 loci encoding the mature hsa-miR-124 (hsa-miR-124-1/-2/-3) showed methylation in cervical cancer cell lines SiHa, CaSki and HeLa as well as in late passages of human papillomavirus (HPV) type 16 or 18 immortalised keratinocytes. Treatment of SiHa cells with a demethylating agent reduced hsa-miR-124 methylation levels and induced hsa-miR-124 expression. In HPV-immortalised keratinocytes increased methylation levels were related to reduced hsa-miR-124 expression and higher mRNA expression of IGFBP7, a potential hsa-miR-124 target gene. Ectopic hsa-miR-124 expression in SiHa and CaSki cells decreased proliferation rates and migratory capacity. Combined hsa-miR-124-1 and/or hsa-miR-124-2 methylation analysis of 139 cervical tissue specimens showed an increasing methylation frequency from 0% in normal tissues up to 93% in cervical carcinomas. Increased methylation levels of hsa-miR-124-1 and hsa-miR-124-2 were significantly correlated with reduced hsa-miR-124 expression in cervical tissue specimens. Combined hsa-miR-124-1 and/or hsa-miR-124-2 methylation analysis of 43 cervical scrapes of high-risk HPV positive women was predictive of underlying high-grade lesions. Conclusions: DNA methylation-based silencing of hsa-miR-124 is functionally involved in cervical carcinogenesis and may provide a valuable marker for improved detection of cervical cancer and its high-grade precursor lesions.

17 September 2014 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
LRL Rodríguez‐Carunchio
L Rodríguez‐Carunchio
ISI Soveral
I Soveral
Renske D.M. SteenbergenRenske D.M. Steenbergen
Renske D.M. Steenbergen
ATA Torné
A Torné
SMS Martinez
S Martinez
MPM del Pino
M del Pino
Objective: Using highly sensitive polymerase chain reaction (PCR) techniques, we reanalysed all cervical carcinomas (CCs) found to be human papillomavirus (HPV)‐negative by Hybrid Capture 2 (HC2) to determine the prevalence of true HPV‐negativity. We also evaluated the characteristics of the patients with tumours with confirmed HPV‐negativity.Design: Observational study.Setting: Barcelona, Spain.Population: A cohort of 136 women with CC (32 adenocarcinomas, 104 squamous cell carcinomas) who had pre‐treatment HC2 testing.Methods: All negative cases were reanalysed and genotyped for HPV using three PCR assays (SPF10, GP5+/6+ and E7‐specific assay).Main outcome measures: Percentage of confirmed HPV‐negative and HPV‐positive tumours. Clinicopathological features and disease‐free survival (DFS) and overall survival (OS) of both groups.Results: Fourteen of 136 women (10.2%) were negative for HPV by HC2. After reanalysis by PCR‐based techniques only 8/136 (5.8%) tumours were confirmed as HPV‐negative, whereas in six cases different HPVs were identified [HPV–11, −16 (two tumours), −18, −45, and −68]. Confirmed HPV‐negativity was more frequent in adenocarcinomas than in squamous cell carcinomas (5/32, 15.6% versus 3/104, 2.9%, respectively; P = 0.017). Patients with CCs with confirmed HPV‐negativity had significantly worse DFS than women with HPV‐positive tumours [51.9 months (95% CI 12.2–91.7 months) versus 109.9 months (95% CI 98.2–121.5 months); P = 0.010]. In the multivariate analysis HPV‐negativity and International Federation of Gynecology and Obstetrics (FIGO) staging were associated with increased risk of progression and mortality.Conclusions: An HC2‐negative result is an uncommon finding in women with CC, but in almost half of these cases HPVs are identified by more sensitive techniques. CCs with confirmed HPV‐negativity are more frequently adenocarcinomas, and seem to be associated with worse DFS.

17 February 2004 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
Renske D.M. SteenbergenRenske D.M. Steenbergen
Renske D.M. Steenbergen
DKDebbie Kramer
Debbie Kramer
BBBoudewijn J. M. Braakhuis
Boudewijn J. M. Braakhuis
PSPeter L. Stern
Peter L. Stern
RVRené H. M. Verheijen
René H. M. Verheijen
PSPeter J. F. Snijders
Peter J. F. Snijders
Background: Cervical carcinogenesis is initiated by infection with high-risk (i.e., carcinogenic) human papillomavirus (HPV) types. The subsequent progression from premalignant cervical intraepithelial neoplasia (CIN) to invasive cancer is driven by both genetic and epigenetic processes. We assessed the role of the gene encoding the adhesion molecule tumor suppressor in lung cancer 1 (TSLC1) in this progression. Methods: We analyzed TSLC1 gene expression by real-time quantitative reverse transcription–polymerase chain reaction, promoter methylation by sodium bisulfite genomic DNA sequencing, and allelic loss by microsatellite analysis in primary keratinocytes, in four non-tumorigenic HPV-immortalized human keratinocyte cell lines, and in 11 human cervical cancer cell lines that were positive for a high-risk HPV DNA type and in normal cervical epithelial cells. We transfected cervical cancer SiHa cells that did not express TSLC1 mRNA with an expression vector containing the TSLC1 complementary DNA (cDNA) or an empty vector and analyzed transfectants for anchorage-independent growth and tumorigenicity in nude mice. We also examined TSLC1 promoter methylation in premalignant cervical lesions and in cervical carcinomas and smears. All statistical tests were two-sided. Results: TSLC1 mRNA was strongly reduced, relative to levels in primary keratinocytes, or absent in 10 (91%) of 11 cervical carcinoma cell lines but in none (0%) of the four HPV-immortalized cell lines (difference = 91%, 95% confidence interval [CI] = 74% to 100%; P = .004). The TSLC1 promoter was hypermethylated, relative to normal foreskin and cervical epithelial cells, in nine (82%) of the 11 cervical carcinoma cell lines but in none (0%) of the four HPV-immortalized cell lines (difference = 82%, 95 CI = 59% to 100%; P = .01). Seven (88%, 95% CI = 47% to 100%) of the eight SiHa/TSLC1 transfectants displayed a marked reduction in anchorage-independent growth (i.e., 0–100 colonies per 5000 cells) compared with none of the four (0%, 95% CI = 0% to 60%) SiHa transfectants bearing the empty vector (i.e., SiHa/hygro transfectants; difference = 88%, 95% CI = 65% to 100%; P = .01) or untransfected SiHa cells. All seven mice (100%, 95% CI = 59% to 100%) injected with untransfected SiHa cells or SiHa/hygro transfectants displayed tumors of at least 50 mm3 by 2–6 weeks after injection compared with none of eight mice (0%, 95% CI = 0% to 37%) injected with the SiHa/TSLC1 transfectants (difference = 100%, 95% CI = 68% to 100%; P<.001). We detected TSLC1 promoter hypermethylation in seven (35%, 95% CI = 15% to 59%) of 20 high-grade CIN lesions (i.e., CIN II and III) and in 30 (58%, 95% CI = 43% to 71%) of 52 cervical squamous cell carcinomas compared with none (0%, 95% CI = 0% to 34%) of nine normal cervical epithelial biopsy samples and none (0%, 95% CI = 0% to 22%) of 12 CIN I lesions (P<.001 for cervical squamous cell cancer versus normal epithelial biopsy samples plus CIN I lesions). Conclusions: TSLC1 gene silencing via promoter hypermethylation is a frequent event in the progression from high-risk HPV–containing, high-grade CIN lesions to invasive cervical cancer.